Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Fuji
Dow
Merck
Julphar
Citi
Boehringer Ingelheim
Colorcon
Cantor Fitzgerald

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203255

« Back to Dashboard

NDA 203255 describes SIGNIFOR LAR, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the SIGNIFOR LAR profile page.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.
Summary for 203255
Tradename:SIGNIFOR LAR
Applicant:Novartis Pharms Corp
Ingredient:pasireotide pamoate
Patents:4
Suppliers and Packaging for NDA: 203255
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255 NDA Novartis Pharmaceuticals Corporation 0078-0641 N 0078-0641-81
SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255 NDA Novartis Pharmaceuticals Corporation 0078-0642 N 0078-0642-81

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAMUSCULARStrengthEQ 20MG BASE/VIAL
Approval Date:Dec 15, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 15, 2021
Regulatory Exclusivity Use:TREATMENT OF PATIENTSWITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
Patent:➤ Try a Free TrialPatent Expiration:Dec 14, 2026Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Oct 25, 2026Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 203255

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKinsey
Cantor Fitzgerald
Cerilliant
Colorcon
Daiichi Sankyo
Express Scripts
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot